{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T19:44:05Z","timestamp":1757619845136,"version":"3.44.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,9,7]]},"DOI":"10.7759\/cureus.91797","type":"journal-article","created":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T02:32:51Z","timestamp":1757298771000},"source":"Crossref","is-referenced-by-count":0,"title":["Nutritional Status as a Risk Factor for the Early Discontinuation of Inhaled Liposomal Amikacin in Mycobacterium avium Complex Pulmonary Disease"],"prefix":"10.7759","author":[{"given":"Hideaki","family":"Yamakawa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chisa","family":"Uzuka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daisuke","family":"Nakatani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Moe","family":"Nomaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomohiro","family":"Oba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rie","family":"Kawabe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shintaro","family":"Sato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keiichi","family":"Akasaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masako","family":"Amano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Araya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hidekazu","family":"Matsushima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa1125","article-title":"Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS\/ERS\/ESCMID\/IDSA clinical practice guideline","volume":"71","author":"Daley CL","year":"2020","unstructured":"Daley CL, Iaccarino JM, Lange C, et al.. Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS\/ERS\/ESCMID\/IDSA clinical practice guideline. Clin Infect Dis. 2020, 71:905-13. 10.1093\/cid\/ciaa1125","journal-title":"Clin Infect Dis"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1159\/000445906","article-title":"Pulmonary disease caused by non-tuberculous mycobacteria","volume":"91","author":"Wassilew N","year":"2016","unstructured":"Wassilew N, Hoffmann H, Andrejak C, Lange C. Pulmonary disease caused by non-tuberculous mycobacteria. Respiration. 2016, 91:386-402. 10.1159\/000445906","journal-title":"Respiration"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2018.01.024","article-title":"Microbiologic outcome of interventions against Mycobacterium avium complex pulmonary disease: a systematic review","volume":"153","author":"Diel R","year":"2018","unstructured":"Diel R, Nienhaus A, Ringshausen FC, Richter E, Welte T, Rabe KF, Loddenkemper R. Microbiologic outcome of interventions against Mycobacterium avium complex pulmonary disease: a systematic review. Chest. 2018, 153:888-921. 10.1016\/j.chest.2018.01.024","journal-title":"Chest"},{"key":"ref4","doi-asserted-by":"crossref","DOI":"10.1164\/rccm.201807-1318OC","article-title":"Amikacin liposome inhalation suspension for treatment-refractory lung disease caused by Mycobacterium avium complex (CONVERT). A prospective, open-label, randomized study","volume":"198","author":"Griffith DE","year":"2018","unstructured":"Griffith DE, Eagle G, Thomson R, et al.. Amikacin liposome inhalation suspension for treatment-refractory lung disease caused by Mycobacterium avium complex (CONVERT). A prospective, open-label, randomized study. Am J Respir Crit Care Med. 2018, 198:1559-69.","journal-title":"Am J Respir Crit Care Med"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2021.03.070","article-title":"Amikacin liposome inhalation suspension for refractory Mycobacterium avium complex lung disease: sustainability and durability of culture conversion and safety of long-term exposure","volume":"160","author":"Griffith DE","year":"2021","unstructured":"Griffith DE, Thomson R, Flume PA, et al.. Amikacin liposome inhalation suspension for refractory Mycobacterium avium complex lung disease: sustainability and durability of culture conversion and safety of long-term exposure. Chest. 2021, 160:831-42. 10.1016\/j.chest.2021.03.070","journal-title":"Chest"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201107-1203OC","article-title":"Prognostic factors of 634 HIV-negative patients with Mycobacterium avium complex lung disease","volume":"185","author":"Hayashi M","year":"2012","unstructured":"Hayashi M, Takayanagi N, Kanauchi T, Miyahara Y, Yanagisawa T, Sugita Y. Prognostic factors of 634 HIV-negative patients with Mycobacterium avium complex lung disease. Am J Respir Crit Care Med. 2012, 185:575-83. 10.1164\/rccm.201107-1203OC","journal-title":"Am J Respir Crit Care Med"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.3390\/pathogens12111331","article-title":"A systematic review of factors associated with mortality among patients with Mycobacterium avium complex lung disease","volume":"12","author":"Fujishima N","year":"2023","unstructured":"Fujishima N, Komiya K, Yamasue M, Hiramatsu K, Kadota JI. A systematic review of factors associated with mortality among patients with Mycobacterium avium complex lung disease. Pathogens. 2023, 12:1331. 10.3390\/pathogens12111331","journal-title":"Pathogens"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.resinv.2024.04.011","article-title":"Body weight loss is a simple and useful indicator of prognosis and predictive tolerability in the first year of nintedanib therapy in patients with interstitial lung disease","volume":"62","author":"Yamakawa H","year":"2024","unstructured":"Yamakawa H, Sato S, Ohta H, et al.. Body weight loss is a simple and useful indicator of prognosis and predictive tolerability in the first year of nintedanib therapy in patients with interstitial lung disease. Respir Investig. 2024, 62:551-7. 10.1016\/j.resinv.2024.04.011","journal-title":"Respir Investig"},{"key":"ref9","unstructured":"Susceptibility testing of mycobacteria, Nocardia spp., and other aerobic Actinomycetes. (2018). Accessed. 2025: https:\/\/clsi.org\/shop\/standards\/m24\/."},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkq536","article-title":"Evaluation of a rapid detection method of clarithromycin resistance genes in Mycobacterium avium complex isolates","volume":"66","author":"Inagaki T","year":"2011","unstructured":"Inagaki T, Yagi T, Ichikawa K, et al.. Evaluation of a rapid detection method of clarithromycin resistance genes in Mycobacterium avium complex isolates. J Antimicrob Chemother. 2011, 66:722-9. 10.1093\/jac\/dkq536","journal-title":"J Antimicrob Chemother"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00170-2018","article-title":"Treatment outcome definitions in nontuberculous mycobacterial pulmonary disease: an NTM-NET consensus statement","volume":"51","author":"van Ingen J","year":"2018","unstructured":"van Ingen J, Aksamit T, Andrejak C, et al.. Treatment outcome definitions in nontuberculous mycobacterial pulmonary disease: an NTM-NET consensus statement. Eur Respir J. 2018, 51:1800170. 10.1183\/13993003.00170-2018","journal-title":"Eur Respir J"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1186\/s12890-024-03261-w","article-title":"Effectiveness of amikacin liposome inhalation suspension for refractory Mycobacterium avium complex pulmonary disease at 6\u00a0months post initiation","volume":"24","author":"Urabe N","year":"2024","unstructured":"Urabe N, Sakamoto S, Tokita N, et al.. Effectiveness of amikacin liposome inhalation suspension for refractory Mycobacterium avium complex pulmonary disease at 6\u00a0months post initiation. BMC Pulm Med. 2024, 24:442. 10.1186\/s12890-024-03261-w","journal-title":"BMC Pulm Med"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1186\/s12890-022-01947-7","article-title":"Impact of chronic co-infection in pulmonary Mycobacterium avium complex disease after treatment initiation","volume":"22","author":"Urabe N","year":"2022","unstructured":"Urabe N, Sakamoto S, Shimanuki Y, et al.. Impact of chronic co-infection in pulmonary Mycobacterium avium complex disease after treatment initiation. BMC Pulm Med. 2022, 22:157. 10.1186\/s12890-022-01947-7","journal-title":"BMC Pulm Med"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200604-571ST","article-title":"An official ATS\/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases","volume":"175","author":"Griffith DE","year":"2007","unstructured":"Griffith DE, Aksamit T, Brown-Elliott BA, et al.. An official ATS\/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med. 2007, 175:367-416. 10.1164\/rccm.200604-571ST","journal-title":"Am J Respir Crit Care Med"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-018-3113-x","article-title":"High mortality in patients with Mycobacterium avium complex lung disease: a systematic review","volume":"18","author":"Diel R","year":"2018","unstructured":"Diel R, Lipman M, Hoefsloot W. High mortality in patients with Mycobacterium avium complex lung disease: a systematic review. BMC Infect Dis. 2018, 18:206. 10.1186\/s12879-018-3113-x","journal-title":"BMC Infect Dis"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofaf118","article-title":"Effects of amikacin liposome inhalation suspension and amikacin resistance development in patients with refractory Mycobacterium avium complex pulmonary disease","volume":"12","author":"Kurahara Y","year":"2025","unstructured":"Kurahara Y, Yoshida S, Osugi A, et al.. Effects of amikacin liposome inhalation suspension and amikacin resistance development in patients with refractory Mycobacterium avium complex pulmonary disease. Open Forum Infect Dis. 2025, 12:ofaf118. 10.1093\/ofid\/ofaf118","journal-title":"Open Forum Infect Dis"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1136\/bmjresp-2014-000050","article-title":"Prevalence and risk factors for chronic co-infection in pulmonary Mycobacterium avium complex disease","volume":"1","author":"Fujita K","year":"2014","unstructured":"Fujita K, Ito Y, Hirai T, Kubo T, Togashi K, Ichiyama S, Mishima M. Prevalence and risk factors for chronic co-infection in pulmonary Mycobacterium avium complex disease. BMJ Open Respir Res. 2014, 1:e000050. 10.1136\/bmjresp-2014-000050","journal-title":"BMJ Open Respir Res"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofae427","article-title":"Clinical predictors of nontuberculous mycobacteria lung disease and coisolates of potential pathogenic microorganisms in noncystic fibrosis bronchiectasis","volume":"11","author":"Wang PH","year":"2024","unstructured":"Wang PH, Shu CC, Sheu CC, et al.. Clinical predictors of nontuberculous mycobacteria lung disease and coisolates of potential pathogenic microorganisms in noncystic fibrosis bronchiectasis. Open Forum Infect Dis. 2024, 11:ofae427. 10.1093\/ofid\/ofae427","journal-title":"Open Forum Infect Dis"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2023.107417","article-title":"Multiple bacterial culture positivity reflects the severity and prognosis as bronchiectasis in Mycobacterium avium complex pulmonary disease","volume":"219","author":"Ito M","year":"2023","unstructured":"Ito M, Furuuchi K, Fujiwara K, et al.. Multiple bacterial culture positivity reflects the severity and prognosis as bronchiectasis in Mycobacterium avium complex pulmonary disease. Respir Med. 2023, 219:107417. 10.1016\/j.rmed.2023.107417","journal-title":"Respir Med"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.157.6.9705017","article-title":"Weight loss is a reversible factor in the prognosis of chronic obstructive pulmonary disease","volume":"157","author":"Schols AM","year":"1998","unstructured":"Schols AM, Slangen J, Volovics L, Wouters EF. Weight loss is a reversible factor in the prognosis of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1998, 157:1791-7. 10.1164\/ajrccm.157.6.9705017","journal-title":"Am J Respir Crit Care Med"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2021.11.008","article-title":"Association of BMI and change in weight with mortality in patients with fibrotic interstitial lung disease","volume":"161","author":"Comes A","year":"2022","unstructured":"Comes A, Wong AW, Fisher JH, et al.. Association of BMI and change in weight with mortality in patients with fibrotic interstitial lung disease. Chest. 2022, 161:1320-9. 10.1016\/j.chest.2021.11.008","journal-title":"Chest"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciae421","article-title":"Nontuberculous mycobacterial pulmonary disease: patients, principles, and prospects","volume":"79","author":"Nguyen MH","year":"2024","unstructured":"Nguyen MH, Haas MK, Kasperbauer SH, et al.. Nontuberculous mycobacterial pulmonary disease: patients, principles, and prospects. Clin Infect Dis. 2024, 79:e27-47. 10.1093\/cid\/ciae421","journal-title":"Clin Infect Dis"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1016\/j.resinv.2025.04.006","article-title":"Early intervention of nutritional education for idiopathic pleuroparenchymal fibroelastosis of interstitial lung disease","volume":"63","author":"Ohta H","year":"2025","unstructured":"Ohta H, Yamakawa H, Ihara S, et al.. Early intervention of nutritional education for idiopathic pleuroparenchymal fibroelastosis of interstitial lung disease. Respir Investig. 2025, 63:472-80. 10.1016\/j.resinv.2025.04.006","journal-title":"Respir Investig"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1016\/s0899-9007(02)01064-x","article-title":"Effect of supplementing a high-fat, low-carbohydrate enteral formula in COPD patients","volume":"19","author":"Cai B","year":"2003","unstructured":"Cai B, Zhu Y, Ma Yi, et al.. Effect of supplementing a high-fat, low-carbohydrate enteral formula in COPD patients. Nutrition. 2003, 19:229-32. 10.1016\/s0899-9007(02)01064-x","journal-title":"Nutrition"},{"key":"ref25","article-title":"High-protein diet during pulmonary rehabilitation in patients with chronic obstructive pulmonary disease","volume":"69","author":"M\u00f8gelberg N","year":"2022","unstructured":"M\u00f8gelberg N, Tobberup R, M\u00f8ller G, Godtfredsen NS, N\u00f8rgaard A, Andersen JR. High-protein diet during pulmonary rehabilitation in patients with chronic obstructive pulmonary disease. Dan Med J. 2022, 69:A03220185.","journal-title":"Dan Med J"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13133675","article-title":"Proposed clinical algorithm for pleuroparenchymal fibroelastosis (PPFE)","volume":"13","author":"Yamakawa H","year":"2024","unstructured":"Yamakawa H, Oda T, Sugino K, et al.. Proposed clinical algorithm for pleuroparenchymal fibroelastosis (PPFE). J Clin Med. 2024, 13:3675. 10.3390\/jcm13133675","journal-title":"J Clin Med"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1016\/j.clnu.2006.01.017","article-title":"ESPEN guidelines on enteral nutrition: cardiology and pulmonology","volume":"25","author":"Anker SD","year":"2006","unstructured":"Anker SD, John M, Pedersen PU, et al.. ESPEN guidelines on enteral nutrition: cardiology and pulmonology. Clin Nutr. 2006, 25:311-8. 10.1016\/j.clnu.2006.01.017","journal-title":"Clin Nutr"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1183\/23120541.00765-2020","article-title":"Pleuroparenchymal fibroelastosis in Mycobacterium avium complex pulmonary disease: clinical characteristics and prognostic impact","volume":"7","author":"Yamamoto Y","year":"2021","unstructured":"Yamamoto Y, Tsujino K, Kuge T, et al.. Pleuroparenchymal fibroelastosis in Mycobacterium avium complex pulmonary disease: clinical characteristics and prognostic impact. ERJ Open Res. 2021, 7:00765-2020. 10.1183\/23120541.00765-2020","journal-title":"ERJ Open Res"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1136\/thorax-2022-219116","article-title":"Prognostic significance of radiological pleuroparenchymal fibroelastosis in Mycobacterium avium complex lung disease: a multicentre retrospective cohort study","volume":"78","author":"Aono Y","year":"2023","unstructured":"Aono Y, Hozumi H, Kono M, et al.. Prognostic significance of radiological pleuroparenchymal fibroelastosis in Mycobacterium avium complex lung disease: a multicentre retrospective cohort study. Thorax. 2023, 78:825-34. 10.1136\/thorax-2022-219116","journal-title":"Thorax"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/406712-nutritional-status-as-a-risk-factor-for-the-early-discontinuation-of-inhaled-liposomal-amikacin-in-mycobacterium-avium-complex-pulmonary-disease","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T02:32:59Z","timestamp":1757298779000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/406712-nutritional-status-as-a-risk-factor-for-the-early-discontinuation-of-inhaled-liposomal-amikacin-in-mycobacterium-avium-complex-pulmonary-disease"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,7]]},"references-count":29,"URL":"https:\/\/doi.org\/10.7759\/cureus.91797","relation":{},"ISSN":["2168-8184"],"issn-type":[{"type":"print","value":"2168-8184"}],"subject":[],"published":{"date-parts":[[2025,9,7]]}}}